This Beaten-Down Growth Stock Has 99% Upside, According to Wall Street
These days, investors can find plenty of reasons to feel nervous about buying stocks. Surging inflation, soaring interest rates, and geopolitical tensions are all legitimate concerns for most businesses.
In these challenging times, investors would do well to remember that difficult economic conditions hardly ever limit the amount of healthcare we need. In 2023, nearly 2 million new cancer cases are projected to occur in the United States, and there's nothing the Federal Reserve can do about it.
's (NASDAQ: NVCR) medical device business can perform well in just about any economic environment, and analysts who follow the stock know it. H.C. Wainwright, an investment bank, recently changed its price target on the stock to $85, which implies a 99% gain from its latest closing price.
Source Fool.com
